Recently the MYD88 mutation has been emerged as a hallmark of WM/LPL, implicating in its diagnosis, management, and treatment (23).1 patient with LPL was diagnosed with IgG4-associated disease 7 years after the diagnosis of hematological disease. This evidence concerns the gene MYD88 and hematologic disorder.